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CCN proteins affect cell proliferation, migration, attachment,
and differentiation. We identified CCN3 as a suppressed gene
following platelet-derived growth factor (PDGF)-BB or -DD
stimulation in a cDNA-array analysis of mesangial cells.
In vitro growth-arrested mesangial cells overexpressed and
secreted CCN3, whereas the addition of the recombinant
protein inhibited cell growth. Induction of mesangial cell
proliferation by PDGF-BB or the specific PDGF b-receptor
ligand PDGF-DD led to downregulation of CCN3 mRNA,
confirming the array study. Specific PDGF a-receptor ligands
had no effect. CCN3 protein was found in arterial smooth
muscle cells, the medullary interstitium, and occasional
podocytes in the healthy rat kidney. Glomerular CCN3 was
low prior to mesangial proliferation but increased as
glomerular cell proliferation subsided during
mesangioproliferative glomerulonephritis (GN). Inhibition of
PDGF-B in mesangioproliferative disease led to
overexpression of glomerular CCN3 mRNA. CCN3 localized
mostly to podocytes in human glomeruli, but this expression
varied widely in different human glomerulonephritides.
Glomerular cell proliferation negatively correlated with CCN3
expression in necrotizing GN. Our study identifies CCN3 as an
endogenous inhibitor of mesangial cell growth and a
modulator of PDGF-induced mitogenesis.
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Increased mesangial cell proliferation and matrix expansion
characterize IgA nephropathy, most types of lupus nephritis,
diabetic nephropathy, and other proliferative glomerular
diseases. Among the most potent mitogens for mesangial cells
are the platelet-derived growth factor (PDGF) isoforms PDGF-
BB and -DD.1–6 Both are overexpressed in glomeruli in various
diseases. Inhibition of PDGF-BB or -DD in mesangioprolifera-
tive nephritis can prevent renal failure, glomerulosclerosis, and
tubulointerstitial fibrosis.1,4–6 Whereas the role of PDGF in
glomerular cell proliferation is thus well established, nothing is
known about modulators of PDGF bioactivity and the feedback
mechanisms that might limit its actions.
In the course of a systematic search for genes that are
downregulated by PDGF-BB or -DD in mesangial cells, we
discovered CCN3 as one of the most prominently suppressed
genes. CCN3, also known as nephroblastoma overexpressed
gene (NOV), belongs to the CCN protein family (Cyr61,
CTGF, nephroblastoma overexpressed gene), which currently
consists of six members: cystein-rich 61 (Cyr61/CCN1),
connective tissue growth factor (CTGF, CCN2), CCN3, and
Wnt-1-induced secreted proteins-1, -2, and -3 (CCN4, 5, 6).
All CCN proteins are involved in the regulation of cell
proliferation, migration, attachment, and differentiation.7
Little is known about CCN3 and the kidney. In the
developing human kidney, the mesonephric and parameso-
nephric ducts as well as the stromal and other tubular cells
expressed CCN3 mRNA.7,8 Very high CCN3 protein levels were
observed in podocytes of meso- and metanephric glomeruli,
whereas in the adult kidney, CCN3 is expressed at a low level
only.8
Given the potent downregulation of CCN3 by PDGFs (see
above) and the overexpression of the PDGF-B and -D chain
in a large number of glomerular diseases, we asked whether
CCN3 represents a downstream target and modulator of
PDGF activity in the glomerulus.
RESULTS
A cDNA array analysis identifies CCN3 as a potently
suppressed gene in PDGF-stimulated HMC
Using the Affymetrix human genome chip U133A,
which detects more than 18 400 transcripts derived from
approximately 14 500 human genes, we found that the gene
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most potently suppressed in PDGF-BB-stimulated human
mesangial cells (HMC) was CCN3 (reduction 6179% in
comparison to cells exposed to medium only; n¼ 3).
Similarly, PDGF-DD stimulation led to a 4877%
downregulation of CCN3 mRNA. Downregulation of
CCN3 in both situations was verified by reverse transcriptase
(RT)-PCR (data not shown).
Growth arrest stimulates CCN3 mRNA and protein expression
in HMC and rat mesangial cells
We next asked whether CCN3 expression in HMC is affected
by their proliferative status. Growth arrest of HMC was
induced by incubation in medium complete with trace
elements (MCDB) medium for 72 h (Figure 1a). MCDB
medium is a serum-free medium, which permits HMC
culture in the absence of growth factors or fetal calf serum
(FCS).9 The growth arrest was reversible since the cells could
be re-stimulated by PDGF-BB to achieve similar DNA
synthesis rates as cells kept in medium with FCS at all time
points (Figure 1a). Growth-arrested HMC exhibited a time-
dependent increase of CCN3 mRNA levels relative to HMC
growing in medium with FCS (Figure 1b). Full-length CCN3
protein could be detected in supernatants of growth-arrested,
but not of growing, HMC (Figure 1c). Potential truncated
Table 1 | Expression pattern of CCN3 in rat and human kidney
Location Rat Human
Glomerulus
Endothelial cells  
Mesangial cells De novo in disease 
Podocytes ++ ++
Parietal epithelial cells  
Circulating leukocytes, platelets ? ?
Arteries
Smooth muscle cells ++ ND
Endothelial cells  ND
Tubules ++ ND
Interstitium
Interstitial cells ++ ND
Macrophages ? ND
ND, not determined; þþ , positive staining; , absent staining; ?, not specified.
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Figure 1 | CCN3 is involved in growth arrest of mesangial cells. (a) Proliferation of HMC cultivated in MCDB (filled bars) or RPMI
media with 10% FCS (open bars). To demonstrate the reversibility of the growth arrest, the cells were stimulated with PDGF-BB (50 ng ml1) for
24 h after incubation with MCBD media (hatched bars). Cell proliferation was assessed by seeding HMC in 96-well plates (Nunc, Wiesbaden,
Germany), growing them to subconfluence and then incubating them in the above media. Data are means7s.d. of four independent
experiments. *Po0.05 versus cells treated with MCDB media for 24 h, #Po0.05. (b) CCN3 mRNA, as detected by real-time RT-PCR and
normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA, following growth arrest in HMC. For this, HMC were switched from RPMI
plus 10% FCS at 0 h to MCDB medium. Data are means7s.d. of three independent experiments. *Po0.05 versus 0 h. (c) Expression of CCN3
protein by western blotting in proliferating HMC (RPMIþ 10% FCS) or following transfer into growth-arrest medium (MCDB). PC, positive
control (supernatant from adrenocortical cell cultures, which are known to secrete CCN3); M, molecular weight markers. One representative
experiment out of two is shown. (d) Proliferating HMC can be growth inhibited by adding recombinant CCN3 protein. A total of 10 000
cells were seeded on day 0 and cultivated in RPMIþ 10% FCS. At day 1, GST-CCN3 (10, 50, 100, and 150 nM) or GST alone (150 nM) was
added and the cells were incubated for a further 3 days. Cell number was counted in duplicate using a Malassez hemocytometer. One
representative experiment out of two is shown.
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CCN3 protein isoforms, which have been described to induce
proliferation in other cell types,10–12 were not observed. Full-
length or truncated CCN3 was not detectable in cell lysates at
any time point (data not shown), indicating that the CCN3
protein was completely secreted.
Similar to the above observations in HMC, CCN3 mRNA
overexpression was also noted in rat mesangial cells after
cultivation in MCDB medium for 16–48 h, but not in RPMI
medium containing 10% FCS (data not shown).
To assess the functional role of extracellular CCN3 in
HMC, we incubated HMC, proliferating in RPMI medium
with 10% FCS, with either recombinant glutathion-S-
transferase (GST)-tagged CCN3 or GST alone. The GST-tag
did not influence the activity of recombinant CCN3 as
described previously.13 After 3 days, numbers of HMC dose-
dependently decreased following incubation with GST-CCN3
in comparison to cells growing in the presence of GST
control protein (Figure 1d).
Ligands of the PDGF b-receptor, but not of the a-receptor,
downregulate CCN3 mRNA expression
PDGF-BB and the specific b-receptor ligand PDGF-DD are
potent mitogens for mesangial cells, whereas ligands of the
PDGF a-receptor, that is PDGF-AA and -CC, usually elicit
lower-level and fewer biological effects in mesangial
cells.5,14,15 In agreement with these observations, stimulation
of HMC with PDGF-BB or -DD resulted in a significant
downregulation of CCN3 mRNA expression after 24 h,
whereas incubation with PDGF-AA or -CC did not influence
the CCN3 mRNA expression (Figure 2).
Expression of the PDGF receptor a- and b-chains is not altered
in HMC stimulated with PDGF-AA or -BB
As HMC express both PDGF-receptors,16 we asked whether a
loop exists whereby PDGFs altered CCN3 release, which in
turn modifies PDGF receptors and thus PDGF-responsive-
ness. However, neither the stimulation of HMC with PDGF-
AA nor with -BB resulted in a significant change of PDGF
a- and b-receptor mRNA (Figure 3).
Expression of CCN3 in normal rat kidney and during
experimental mesangioproliferative glomerulonephritis
In normal adult rat kidney, CCN3 was expressed in arterial
smooth muscle cells and in the medullary interstitium (Figure
4a–c) (Table 1). In addition, collecting duct cells were also
positive as demonstrated in serial sections using antibodies for
CCN3 and aquaporin-2 (Figure 4g and h). About 20% of the
rats exhibited CCN3 expression in a podocyte-specific pattern
(Figures 4e, 5a and b). No convincing CCN3 positivity was
detected in the mesangium or glomerular endothelium (Figure
4d). Constitutive expression of CCN3 in glomeruli was
confirmed by RT-PCR (Figure 6a).
Anti-Thy 1.1 mesangioproliferative glomerulonephritis
(GN) in rats is characterized by early mesangiolysis, a phase
of overshooting mesangial cell proliferation and matrix
accumulation and subsequent resolution of disease over the
next 28 days.17 In nephritic rats, we detected CCN3 protein
within the expanded mesangium in addition to the
constitutive podocytic CCN3 expression at day 9 after disease
induction (Figures 4f, 5c and d) (Table 1). Glomerular CCN3
mRNA expression decreased during the early phase of
mesangial damage and subsequently was overexpressed
starting on day 4 after disease induction (Figure 6a). The
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Figure 2 | Incubation with PDGF-BB or -DD, but not PDGF-AA
or -CC, results in a downregulation of CCN3 mRNA. PDGF-BB
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Figure 3 | Incubation with PDGF-BB or -AA does not affect the
expression the PDGF receptor a- and b-chain mRNA in HMC.
Real-time RT-PCR-based expression data of PDGF receptor (a) a- or
(b) b-chain normalized to glyceraldehyde-3-phosphate dehydrogenase
mRNA. Data are means7s.d. of four independent experiments.
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10.4-fold peak induction of CCN3 mRNA expression in
glomeruli occurred about 2 days after the peak of glomerular
cell proliferation (Figure 6a), which in this phase of the
disease is almost exclusively due to mesangial cell prolifera-
tion.17 Western blot analysis of glomerular protein extracts
confirmed the overexpression of full-length 48 kDa CCN3
protein on days 7 and 9 after disease induction (Figure 6b). A
second CCN3 isoform (75 kDa) was also overexpressed
(Figure 6b).
Antagonism of PDGF-B restores CCN3 mRNA expression
in experimental mesangioproliferative GN
Antagonism of PDGF-B using antagonistic aptamers from
day 3 until day 6 after anti-Thy 1.1 nephritis induction results
in a significant reduction of mesangial cell proliferation.1 In
glomeruli isolated from nephritic rats, which had been
treated with PDGF-B aptamers, CCN3 mRNA expression on
day 7 was significantly higher as compared to nephritic
animals receiving inactive control compound (PEG40)
(Figure 6c).
Decreased CCN3 protein expression correlates with reduced
glomerular cell proliferation in human necrotizing GN
In normal human kidney, a predominantly glomerular
staining with a podocytic expression pattern of CCN3 could
be observed in almost all glomeruli (Figure 7a). Outside of
glomeruli, nonspecific background staining precluded an
unequivocal detection of positive cells (Table 1). To assess
disease-specific alterations, we measured the CCN3-positive
glomerular area by morphometry in a large number of
human biopsies. Whereas the positively stained area was
relatively constant within a particular biopsy, a wide
variability was observed within disease entities and between
different diseases, so that no specific pattern of altered CCN3
expression was detected (Figure 7a and b).
To specifically assess the relationship between glomerular
CCN3 expression and cell proliferation, we evaluated the
glomerular immunostaining for CCN3, the proliferation-
associated protein mib/Ki-67 and p27, a negative regulator of
cell proliferation. Whereas glomerular cell proliferation in
most disease entities was very low and no clear relationship
with CCN3 evolved, in necrotizing GN, we observed a
significant negative correlation between CCN3 protein
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Figure 4 | CCN3 protein expression in kidneys of healthy and
nephritic rats. In the healthy rat kidney, (a) CCN3 is expressed in
arterial smooth muscle cells, (b) in the medullary interstitium, (c) and
in some cells of the collecting duct. (d) CCN3 staining is absent in the
mesangium. (e) About 20% of the normal rats expressed CCN3 in a
podocyte pattern. (f) On day 9 after induction of
mesangioproliferative anti-Thy 1.1 nephritis, an apparent de novo
expression of the CCN3 protein in the mesangium (open arrow) in
addition to the constitutive podocytic expression (filled arrows) was
observed. Serial sections labeled for (g) CCN3 and (h) aquaporin-2
identifies the CCN3-positive tubular segments as collecting ducts.
Original magnifications:  200 in A, E, G, H;  600 in B, C, D, F.
a
c
b
d
Figure 5 | Podocytic and mesangial CCN3 protein expression in
kidneys of healthy and nephritic rats. The podocytic CCN3 protein
expression in the healthy rat kidney was confirmed by double
immunostaining for CCN3 (blue color) and nuclear WT-1 expression
(brown) (a, original magnification  200; b, original magnification
 1000). In the nephritic rat at day 9 after induction of anti-Thy
1.1 nephritis, the activated mesangium exhibits de novo expression
of a-smooth muscle actin (blue). In addition to the constitutive
podocytic CCN3 expression (brown), CCN3 protein could be
detected in a (c) diffuse or (d) spotty pattern within the activated
mesangium as indicated by the arrows (original magnification
 600).
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expression and numbers of MIB-positive cells and a positive
correlation between CCN3 and numbers of p27-positive cells
(Figure 7a and c).
DISCUSSION
In this study, we identify CCN3 in the glomerulus as a potent
endogenous growth inhibitor of mesangial cells as evidenced
by (1) increased CCN3 mRNA expression in growth-arrested
human as well as rat MC in comparison to proliferating cells,
(2) the detection of extracellular full-length CCN3 protein in
mesangial cell supernatants and glomerular lysates, and (3)
reduced cell proliferation of HMC following the addition of
recombinant CCN3 protein.
The role of CCN3 in regulating cell proliferation has been
described variably. Overexpression of CCN3 in chicken
embryonic fibroblasts, glioblastoma or Ewing’s sarcoma cell
lines inhibits their growth in vitro and in vivo.7,13,18 In glioma
and choriocarcinoma cell lines, CCN3 mediates connexin 43-
induced growth inhibition,19,20 and in chronic myeloid
leukemia, the constitutively active BCR-ABL protein kinase
downregulated CCN3 expression. Transfection or incubation
of BCR-ABLþ cells with CCN3 inhibited leukemia cell
proliferation.21 However, in other situations, CCN3 was
described to promote growth or to amplify the activity of
FGF2 and PDGF.22–24 In part, these variable functions of
CCN3 may relate to its complex biology given that for
normal cell proliferation the balance of full-length and
truncated CCN3 proteins is critical and the biological activity
may be context dependent.7 Further post-translational
modifications or the subcellular localization might be
important for the biological functions.10–12 For example,
Liu et al.24 described an induction of cell proliferation by an
approximately 40 kDa CCN3 protein, purified from super-
natants of transfected 293 cells, whereas our primary
mesangial cells secreted a 48 kDa CCN3 protein. In another
study, Lafont et al.22 described an induction of proliferation
by recombinant CCN3 in the C2C12 myoblast cell line.
However, in contrast to the experimental conditions
employed in our study, Lafont et al. coated culture plates
with recombinant CCN3, which resulted in increased
adhesion of the cells and might thereby have affected cell
proliferation in a different manner.
The second major finding of this study was that CCN3 in
mesangial cells and glomeruli is regulated by PDGF-BB and
-DD, that is the two known ligands of the PDGF b-receptor
chain. Consistent with this, the treatment of nephritic rats
with PDGF-B-specific aptamers resulted in both a pro-
nounced reduction of mesangial cell proliferation1 and
higher expression of CCN3 mRNA as compared to control
animals. In vitro, the decrease in mesangial cell CCN3
production in response to PDGF-BB (Figure 2a) directly
mirrored PDGF-BB and -DD-induced mesangial cell pro-
liferation, which is maximal after 24 h.16 In contrast, selective
ligands of the PDGF a-receptor, that is PDGF-AA and -CC,
did not affect CCN3 mRNA expression, indicating that the
downregulation of CCN3 is mediated by the PDGF
b-receptor chain. These data are in accordance with
the finding that PDGF-BB and -DD are potent mitogens
for mesangial cells in vitro and in vivo, whereas PDGF-AA
usually elicits lower-level and fewer biological effects in
mesangial cells despite their expression of the PDGF a-
receptor.14,15 We also excluded, at least at the mRNA level,
that the interaction between PDGFs and CCN3 involves
modulation of the mesangial cell PDGF receptor expression.
This was of importance given that in glioblastoma cells, the
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Figure 6 | Glomerular expression of CCN3 in the course of anti-
Thy1.1 mesangioproliferative nephritis. Rats were killed at 4 h and
at days 1, 2, 4, 7, 9, 14, 21, and 28 after disease induction (n¼ 9 each).
(a) RNA was isolated from the glomeruli and the expression of CCN3
mRNA was measured by real-time RT-PCR. The figure shows the
transcript expression (means7s.d.) in relation to the expression in
non-nephritic rats. A parallel evaluation of proliferating cells per
glomerular cross-section shows that its peak antedates the peak of
CCN3 mRNA. Data are depicted on a half logarithmic scale. *Po0.05
versus non-nephritic rats. (b) The expression of the CCN3 protein was
detected by western blot analysis (n¼ 4 each, PC, positive control, M,
molecular weight markers). (c) Glomerular CCN3 mRNA expression in
nephritic rats treated with PDGF-B specific aptamers or PEG40 from day
3 to 6 after disease induction. Rats were killed at day 7 (n¼ 4 each).
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expression of the PDGF receptor a-chain is upregulated
by CCN3.25
Third, we provide the first data on the CCN3 expression
pattern in rat and human kidney. We found that renal
cells expressing CCN3 in normal kidney largely overlap
with those producing PDGF-B, -C, and -D.5,26,27 Although
the physiologic function of both PDGF- and CCN3-
expression in some locations, such as the collecting duct, is
completely unknown, we have recently provided first
evidence that the production of these growth factors in the
podocyte may serve as an important regulatory mechanism
of intraglomerular cell proliferation. Thus, overexpression of
PDGF-D in murine podocytes resulted in extensive pro-
liferative changes within the glomerular tuft.28 It is therefore
conceivable that in normal glomeruli, a finely tuned balance
between pro- and anti-proliferative factors, such as the
PDGF-B and -D/CCN-3 system produced by podocytes,
governs the physiological glomerular cell turnover. At
least in rat glomeruli, we only detected the full-length
CCN3 protein (48 kDa), which inhibits cell proliferation, and
a 75 kDa isoform, which represents a dimer, that is still
resistant to denaturing conditions used for western blot.7
Potential shorter isoforms, which appear to be involved in
malignant transformation and growth induction,12 were not
detected.
The fourth major finding of the study is that in
experimental mesangioproliferative nephritis, an apparent
de novo expression of CCN3 in the mesangium can be
detected. In normal rat glomeruli, CCN3 protein is largely
confined to podocytes. During the peak proliferative phase of
anti-Thy1.1 nephritis, glomerular CCN3 mRNA expression
increased and the protein also appeared in the activated
mesangium. Thus, it appears that, as in the case of other
growth factors, such as vascular endothelial growth factor,
CCN3 is normally acting as a paracrine mediator but that
there may be an autocrine component in disease. The
maximal glomerular CCN3 mRNA and protein expression
occurred at about day 9 after disease induction. This time
point is remarkable, as it followed the peak intraglomerular
cell proliferation by 2 days and the peak PDGF-B mRNA
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Figure 7 | CCN3 protein expression in diseased human kidney. (a) In human glomeruli, CCN3 is expressed in a podocyte-specific
pattern. CCN3 glomerular staining pattern of healthy kidney as well as in biopsies of patients with minimal change nephropathy and
necrotizing GN are shown. In serial sections, p27-positive glomerular cells were demonstrated in the same glomeruli. (b) CCN3 protein
immunostaining in glomeruli of renal biopsies from patients with various renal diseases. The percentage of positively stained area in each
glomeruli was measured by computer-based morphometry. Data are means7s.d. of eight biopsies each. (c) Renal biopsies from patients
with necrotizing GN and IgA nephropathy were stained for CCN3, mib/Ki-67, or p27. The relative glomerular area staining positively for
CCN3, as determined by computer-based morphometry, was correlated to the number of MIB/Ki-67 or p27-positive cells per glomerular
cross-section (n¼ 8). In necrotizing GN, but not in IgA, nephropathy glomerular cell proliferation correlated negatively with CCN3 expression.
Statistics were performed using the two-tailed Pearson’s test.
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expression in the glomeruli by 5 days.5 The time course
thereby is consistent with our hypothesis that CCN3 may
be a (patho-)physiological regulator, which limits mesangial
cell proliferation in vivo and which may contribute to
the restitution of normal glomerular morphology. In the
anti-Thy 1.1 nephritis model, the latter usually occurs in
the course of 4 weeks.17
Two other members of the CCN-family have also been
invoked in the pathogenesis of mesangioproliferative anti-
Thy 1.1. CCN1 (Cyr61) is upregulated in nephritic glomeruli
between days 3 and 7 after disease induction. However, in
contrast to CCN3, CCN1 remains exclusively expressed by
podocytes and inhibits PDGF-induced mesangial cell migra-
tion rather than proliferation.29 A second member, CCN2
(CTGF), is also strongly upregulated in extracapillary and
mesangial proliferative lesions and in areas of periglomerular
fibrosis. In anti-Thy 1.1 nephritis, CCN2 mRNA over-
expression was already detected at day 1 after disease
induction and maximum expression was reached by day
7.30 In contrast to CCN3, which may be involved in
glomerular healing (see above), CCN2 acts as a downstream
mediator of TGF-b and appears to be involved in the
pathogenesis of glomerulosclerosis and tubulointerstitial
fibrosis.19,30
In the final part of this study, we assessed the CCN3
expression pattern in a large collection of human renal
biopsies with a variety of glomerular pathologies. Although
no disease-specific pattern evolved, we noted in the
glomerular disease with the most intense inflammatory and
proliferative activity, namely necrotizing GN, that the CCN3
expression correlated negatively with glomerular cell pro-
liferation and positively with the number of p27-positive
nuclei. As p27 is a cell cycle inhibitor, levels are high in
quiescent mesangial cells in vitro as well as in vivo31–33 and
reduced upon induction of mesangial cell proliferation in
vitro and during anti-Thy1.1 nephritis.31,32 Our observations
in human necrotizing GN are therefore consistent with the
assumed role of CCN3, whereby high levels are antiproli-
ferative and low levels permit a proliferative response in
glomeruli.
Up to now, the participation of other members of the
CCN family in the pathogenesis of human renal disease is
largely unknown. Some data are available, which invoke
CCN2 (CTGF) in the development of renal fibrosis. CCN2
mRNA expression is increased in diabetic nephropathy, IgA
nephropathy, chronic transplant rejection, crescentic GN,
focal and segmental glomerulosclerosis, lupus nephritis, and
membranoproliferative GN.19,34,35
In conclusion, we identify CCN3 as the first endogenous
inhibitor of mesangial cell growth and as a negative feedback
regulator of the important mitogens PDGF-BB and -DD. We
also add CCN3 to a growing list of podocyte-derived growth
factors, which may convert the proliferative activity within
the glomerular tuft. A better understanding of such
regulatory systems may yield novel therapeutic approaches
to glomerular diseases.
MATERIALS AND METHODS
Mesangial cell culture
Primary HMC were obtained from Biowithaker (Verviers, Belgium)
and were cultivated as described.36 Rat mesangial cells were
established and maintained as described previously.37,38
Affymetrix gene chip array
Growth-arrested HMC were stimulated with PDGF-BB (10 ng ml1;
Sigma-Aldrich, Deisenhofen, Germany), PDGF-DD (100 ng ml1;
a kind gift of W LaRochelle, Curagen, Branford, CT, USA), or with
RPMI 1640 alone as described.16 After cultivation for 24 h, the cells
were lysed and RNA was isolated, reverse transcribed into double-
stranded cDNA and subsequently transcribed into biotinylated
cRNA probes. The probes were finally hybridized to an Affymetrix
human Genome U133A microarray as described.16
Mesangial cell culture experiments
Subconfluent HMC were incubated for 0, 16, 24, 48, or 72 h in
MCDB-media (Sigma-Aldrich) or supplemented RPMI 1640
medium.36 After 72 h in MCDB medium, PDGF-AA (100 ng ml1;
Sigma-Aldrich), PDGF-BB (50 ng ml1), PDGF-CC (5 ng ml1; a
kind gift of U Eriksson, Ludwig Institut for Cancer Research,
Stockholm, Sweden), or PDGF-DD (100 ng ml1) in MCDB with
100 mg ml1 of streptomycin and 100 U ml1 penicillin were added
and the cells were incubated for 0.5, 1, 2, 4, 8, 24, or 48 h.
Cell proliferation was assessed as described.16
For the incubation of HMC with recombinant CCN3 protein,
10 000 cells were seeded in 500 ml of complete RPMI medium with
10% FCS in a 24-well plate at day 0. At day 1, recombinant CCN3
protein, tagged with GST or GST alone, produced as described,13 was
added to a final concentration of 10, 50, 100, and 150 nM GST-CCN3
or 150 nM GST. Cells were counted using a Malassez hemocytometer
at day 4 (n¼ 4).
Rat model of mesangioproliferative GN
All animal experiments were approved by the local review boards.
Anti-Thy 1.1 mesangial proliferative GN was induced in male Wistar
rats (Charles River, Sulzfeld, Germany) weighing 180 g, by injection
of 1 mg kg1 anti-Thy 1.1 monoclonal antibody (clone OX-7;
European Collection of Animal Cell Cultures, Salisbury, England).
To study the kinetics of CCN3 expression during anti-Thy 1.1
nephritis, 81 rats received anti-Thy 1.1 monoclonal antibody and
were killed at time points 4 h, day 1, 2, 4, 7, 9, 14, 21, and 28 after
monoclonal antibody injection (n¼ 9 each). Following killing, renal
tissue as obtained and glomeruli were isolated by differential sieving.39
To study the effects of PDGF-B antagonism in vivo, anti-Thy1.1
mesangioproliferative GN was induced in male Wistar rats as
described above. Rats received twice-daily intravenous injections of
0.33 mg PDGF-B-specific aptamers (n¼ 5) or control/PEG40
(n¼ 4), starting at day 3 after the induction of anti-Thy1.1 GN as
described previously.1,4 Renal biopsies were obtained at day 7.
Real-time quantitative RT-PCR
Total RNA was isolated from HMC or rat mesangial cells using the
Invisorb Spin Cell-RNA Mini Kit (Invitek, Berlin, Germany) or from
isolated glomeruli using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). RNA purity determination, cDNA synthesis, and RT-
PCR were performed as described.16 Primer sequences are listed in
Table 2. Glyceraldehyde-3-phosphate dehydrogenase cDNA ampli-
fication was used as an internal standard.
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Western blot analysis
Supernatants of growing or growth-arrested cells were centrifugated
for 5 min at 10 000 g. The cells were lysed as described.16 The
proteins from supernatant and cell lysates were concentrated using
heparin sepharose. The heparin sepharose was washed four times
with phosphate-buffered saline containing protease inhibitors,
dissolved in phosphate-buffered saline/protease inhibitor and
incubated with 500 mg protein over night at 41C. The complexes
were washed with phosphate-buffered saline/protease inhibitor and
the proteins were eluated with 100 ml Laemmli buffer without
bromophenol blue (10 min 951C). A 30 ml probe was loaded in each
lane and western blot analysis was performed as described,40 using a
polyclonal antibody against CCN3 (K19M), which recognizes a
C-terminal 19-aminoacid peptide of human CCN3.11 As a positive
control, a supernatant from adrenocortical cell cultures, which are
known to secrete CCN3, was used.
Immunohistochemistry in rat and human tissues
Immunohistochemistry was performed in methyl Carnoy’s fixed,
paraffin-embedded tissue sections as described.27 CCN3 expression
was assessed using the polyclonal rabbit anti-CCN3 antibody
K19M.11 Glomerular cell proliferation was analyzed using a mouse
monoclonal antibody to the MIB-1/Ki-67 antigen (clone MIB-1,
DAKO, Hamburg, Germany). In addition, we stained for the cell
cycle inhibitor p27 (clone 57, BD Biosciences, Erembodegem,
Belgium). Negative controls consisted of substitution of the primary
antibody with non-immune rabbit IgG or irrelevant monoclonal
mouse IgG (DAKO). For the double immunostaining of WT-1 and
CCN3, sections were first stained for WT-1 (sc-192, Santa Cruz, CA,
USA) using 3,30diaminobenzidine as a chromogen as described
above, followed by detection of CCN3 using the blue alkaline
phosphatase substrate kit III (Vector, Gru¨nberg, Germany). In the
case of CCN3 and a-smooth muscle double staining, the sections
were stained first for CCN3 (3,30diaminobenzidine staining)
followed by the staining for a-smooth muscle actin followed by
the blue alkaline phosphatase substrate kit III.
Sections of human biopsies were obtained from healthy kidney
and patients with IgA nephropathy, lupus nephritis, necrotizing GN,
membranous nephropathy, minimal change nephropathy, benign
nephrosclerosis, glomerulosclerosis, focal segmental glomerulo-
sclerosis, and transplant glomerulopathy (n¼ 8 each). Biopsies
contained between 1 and 26 glomeruli per section. Formalin-fixed
paraffin-embedded human biopsy sections were pretreated with
unmasking solution in a microwave and blocked with host serum
prior to incubation with the antibodies.
Immunohistochemical staining was analyzed by computer-based
morphometry (Soft Imaging system GmbH, Mu¨nster, Germany).
The relative area staining positively for CCN3 in each glomerulus
was calculated. For p27 and MIB staining, positively stained cells per
glomerulus were counted. In all analyses, the investigator was
unaware of the origin of the slides.
Statistical analysis
All values are expressed as means7s.d. Statistical significance (defined
as Po0.05) was evaluated using analysis of variance and Bonferroni
t-tests, and the two-tailed Pearson’s test, where appropriate.
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